{
  "url": "https://www.law.cornell.edu/regulations/new-york/12-NYCRR-441.1",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 12 ยง 441.1 - Definitions",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 12 ยง 441.1 - Definitions\n\nState Regulations\n(a) \"Compound drug\" means a drug that is created by combining one or more active\npharmaceutical ingredients, and/or one or more inactive ingredients, to meet\nspecific patient medical needs that are not met with U.S. Food and Drug\n\nAdministration (\"FDA\")-approved prescription drugs, FDA-approved\nnon-prescription drugs, or other drugs commercially available in the\nmarketplace. For the purposes of this Part, a compound drug shall, at all\ntimes, be subject to federal law governing compounding, including title 21, United State Code, sections 353a, 353a-1 and 353b. A compound drug that\nincorporates a drug identified in Phase A or B of the Formulary or FDA-approved\nnon-prescription drug may only be dispensed for the route of administration\n(oral, topical or systemic) for which it is FDA-approved. Prior authorization\nis required for all compound drugs prior to prescription and/or dispensing of\nsuch drug. (b) \"Accident or injury\"\nmeans any accident occurring in the course of employment or any alleged\naccident that results in personal injury which has caused or will cause a loss\nof time from regular duties of one day beyond the working day or shift on which\nthe accident or alleged accident occurred, or which has required or will\nrequire medical treatment beyond ordinary first aid or more than two treatments\nby a person rendering first aid; or any disease or alleged disease claimed to\nhave been caused by the nature of the employment and contracted therein. An\naccident or injury may also be referred to as a Disability event. (c) \"Dispense,\" \"dispensed,\" or \"dispensing\"\nmeans\n(1)\nthe furnishing of a drug upon a\nmedical prescription, or\n(2)\nthe\nfurnishing of drugs directly to a patient by a medical provider acting within\nthe scope of his or her practice and pursuant to the dispensing limitations set\nforth in section\n6807\n(2)\nof the Education Law. (d) \"FDA-approved drug\" means a\nprescription or nonprescription drug that has been approved by the FDA under\nthe federal Food, Drug, and Cosmetic Act, title 21, United States\n\nCode, section\n301\net seq. for the route of\nadministration (oral, topical or systemic) prescribed. (e) \"FDA OTC Monograph\" means the data\nstandards manual (DSM) established by the FDA setting forth acceptable\ningredients, doses, formulations, and labeling for a class of over the counter\ndrugs. (f) \"Generic drug\" means an\nFDA-approved drug that is therapeutically equivalent to a brand name drug, as\ndetermined by the FDA's designation of the drug with the Therapeutic\n\nEquivalence Evaluation Code designation as an \"A\" product in the \"Approved Drug\n\nProducts with Therapeutic Equivalence Evaluations\" (commonly referred to as the\n\nOrange Book), irrespective of dosage for the route of administration (oral, topical or systemic) prescribed. A brand name drug may not be dispensed when a\ngeneric version of the same active ingredient is commercially available in a\ndifferent strength/dosage. For example, if a drug is available generically in\n5mg and 10mg tablets and brand name only in 7.5mg tablets, the 7.5mg would be\nconsidered non-formulary and may not be dispensed without prior\nauthorization. (g) \"Carrier's\n\nPhysician\" means a physician or physicians, licensed by New York State, or the\nappropriate state where the professional practices, who is: 1. employed or contracted by the insurance\ncarrier or self-insured employer; or\n2. is employed by a URAC accredited company\nretained by the insurance carrier or self-insured employer through a contract\nto review claims requests for non-formulary agents and advise the insurance\ncarrier or self-insured employer; and\n3. is not employed or contracted by the\ncarrier or self-insured employer's pharmacy benefits\nnetwork. (h) \"Formulary\"\nmeans the New York Workers' Compensation Formulary which is a list of\nprescription and over-the-counter drugs for work-related injuries that is\nincorporated by reference in section\n441.2\nof this Part and that must\nbe used to prescribe medication for all accidents or injuries. The Formulary\nincludes medications available in Phase A and B; and, also includes a list of\nmedications available for Perioperative periods that may be prescribed without\n\nPrior Authorization during the applicable Phase or Perioperative\nperiod. (i) \"Non-Formulary drug\"\nmeans a drug that does not appear on the Formulary and which is one of the\nfollowing: an FDA-approved prescription drug; an FDA-approved nonprescription\ndrug; or a nonprescription over the counter drug that is marketed pursuant to\nan FDA OTC Monograph. Non-Formulary drugs do not include non-FDA approved drugs\nand such drugs may not be prescribed. (j) \"Over-the -counter drug\" means a drug\nthat is available without a prescription. The carrier or pharmacy benefits\nmanager should be billed for over-the-counter drugs included in the Formulary. Over-the- counter drugs that are not included on the Formulary require Prior\n\nAuthorization or direct payment by the claimant (which thereafter may be\nsubmitted to the carrier in a reimbursement request). (k) \"Perioperative Formulary drug\" are those\ndrugs listed in the Perioperative Drug Formulary where the drug is prescribed\nfor work-related injuries in accordance with subdivision (c) of section\n441.4\nherein. (l) \"Phase A drug\" are those drugs listed in\n\nPhase A of the Formulary. Phase A drugs may be prescribed and dispensed without\n\nPrior Authorization and Medical Treatment Guidelines corroboration when\nprescribed in accordance with subdivision (a) of section\n441.4\nherein. (m) \"Phase B drug\" are those drugs listed in\n\nPhase B of the Formulary and may be prescribed and dispensed without Prior\n\nAuthorization and Medical Treatment Guidelines corroboration when prescribed in\naccordance with subdivision (b) of section\n441.4\nherein. (n) \"Prior Authorization process\" means the\npre-approval review procedure initiated by the medical provider that is\nconducted prior to the prescribing or dispensing of a Non-Formulary drug; a\nbrand-name drug when a Generic drug is available; or a Formulary drug\nprescribed not in accordance with the applicable Phase of the Formulary or in\naccordance with applicable Medical Treatment Guidelines. (o) \"Prior Authorization\" means the carrier's\napproval of a Prior Authorization request initiated by the medical\nprovider. (p) \"Refill\" means a fill\nof a prescription that is authorized at the point in time when the provider\nwrites the original prescription and the number of such fills is explicitly\nincluded in the original prescription. (q) \"Renewal\" means a prescription that the\nclaimant has been taking but for which there are no available refills and must\nbe reinitiated by the provider writing a new prescription. (r) \"URAC\" means the Washington DC-based\nnon-profit organization of that name that helps promote health care quality\nthrough the accreditation of organizations involved in medical care\nservices. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 12\nยง\n441.1\n\nAdopted\n\nNew\n\nYork State Register June 5, 2019/Volume XLI, Issue 22, eff. 6/5/2019\n\nAmended\n\nNew\n\nYork State Register September 1, 2021/Volume XLIII, Issue 35, eff. 9/1/2021\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "regulation",
  "source_index": 50778
}